サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1178083

血栓溶解剤の世界市場：タイプ別、用途別、流通チャネル別、地域別?業界規模、シェア、動向、競合、機会、予測、競合（2017年～2027年）

Clot Buster Drugs Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2017-2027 Segmented By Type, By Application, By Distribution Channel, By Region
出版日: | 発行: TechSci Research | ページ情報: 英文 115 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.90円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

血栓溶解剤の世界市場：タイプ別、用途別、流通チャネル別、地域別?業界規模、シェア、動向、競合、機会、予測、競合（2017年～2027年）
出版日: 2022年12月01日
発行: TechSci Research
ページ情報: 英文 115 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の血栓溶解剤の市場規模は、予測期間（2023年～2027年）中に目覚ましいCAGRで成長すると予測されています。

心臓発作や脳卒中への即時応答のための効果的な医薬品の需要の急増、心血管疾患の増加、虚血性脳卒中のリスクの高まりは、市場の成長を促進しています。

当レポートでは、世界の血栓溶解剤市場について調査分析し、製品概要、市場の展望、競合情勢など、体系的な情報を提供しています。

目次

第1章 製品概要

第2章 調査手法

第3章 COVID-19が世界の血栓溶解剤市場に与える影響

第4章 エグゼクティブサマリー

第5章 VOC (顧客の声)

  • 選好：薬剤タイプ別
  • 血栓溶解剤の需要が高まる要因
  • 血栓溶解剤の採用に対する障壁
  • ブランド認知度

第6章 臨床試験

  • 進行中の臨床試験
  • 完了した臨床試験
  • 中断した臨床試験
  • 臨床試験分析

第7章 特許分析

  • 特許取得済み（2016年～2020年）
  • 特許出願

第8章 世界の血栓溶解剤市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • タイプ別（フィブリン特異的薬剤、非フィブリン特異的薬剤）
    • 用途別（心筋梗塞、肺塞栓症、深部静脈血栓症、急性虚血性脳卒中、その他）
    • 流通チャネル別（小売薬局、病院薬局、オンライン薬局）
    • 企業別（2021年）
    • 地域別
  • 製品市場マップ

第9章 北米の血栓溶解剤市場の展望

第10章 欧州の血栓溶解剤市場の展望

第11章 アジア太平洋の血栓溶解剤市場の展望

第12章 南米の血栓溶解剤市場の展望

第13章 中東およびアフリカの血栓溶解剤市場の展望

第14章 市場力学

  • 促進要因
  • 課題

第15章 市場の動向と開発

第16章 競合情勢

  • F. Hoffmann-La Roche AG
  • Taj Pharmaceuticals Limited
  • Eumedica Pharmaceuticals SA
  • SEDICO Pharmaceutical Company
  • Mochida Pharmaceutical Co., Ltd
  • Medac GmbH
  • Microbix Biosystems Inc
  • Crinos S.p.A.

第17章 戦略的提言

第18章 当社について・免責事項

目次
Product Code: 8207

Global clot buster drugs market is anticipated to grow with an impressive CAGR value in the mentioned forecast years 2023-2027 on the account of increasing instances of heart attacks and strokes. Surge in the demand for the effective pharmaceuticals for the immediate response to heart attacks and strokes is further driving the growth of the global clot buster drugs market in the upcoming five years.

Clot buster drugs are the heart diseases dugs that help in dissolving the blood clots in case of blockage in the veins, that are often cause of strokes and heart attack. Clot buster drugs are also known as thrombolytic therapeutics that are a class of heart medications that are often administered under supervisions in the hospitals through an intravenous injection. Use of these drugs helps in preventing ongoing damage to the heart during heart attack or deteriorating condition due to ischemic stroke. These drugs are also utilized in case the clots are formed in other parts of the blood vessels in the body. Side-effects of these drugs include excessive blood loss from injuries or cuts, allergic reaction to the clot buster drugs, low blood pressure, unusual bleeding in urine, stool etc. thus concerned and monitored administration is a necessity.

Cardiovascular Diseases Drive Market Growth

Increasing instances of cardiovascular diseases are driving the growth of the global clot buster drugs market in the upcoming five years. Rapidly increasing instances of heart attacks, and strokes is also supporting the growth of the global clot buster drugs market in the next five years. Stroke is the 5th leading cause of death in the United States. Increasing instances of strokes demands for the immediate response to the situation where clot buster drugs can help the situation and dissolve the blood clot pooling in the veins thus creating lower blood pressure. Mortality rate among the population is increasing due to strokes and further aiding the growth of the global clot buster drug market. Death rate from stroke among men in the United States is 37.6 per 100,000 population and that in females is 36.1 per 100,000 population.

Also, increasing risks of ischemic strokes among the global population is further substantiating the growth of the global clot buster drugs market in the next five years. The prevalence of ischemic stroke in women was slightly higher than that in men in 2017. In total, there were 82.42 million people who had experienced an ischemic stroke of which 41.81 million were women and 40.61 were men.

Market Segmentation

The global clot buster drugs market segmentation is based on type, application, distribution channel, regional distribution, and competitive landscape. Based on type, the market is divided between fibrin specific drugs and non-fibrin specific drugs. Further segmentation of fibrin specific drug is defined into tissue plasminogen activator, Reteplase, Tenecteplase, and others. Whereas non-fibrin specific drugs are differentiated into urokinase, streptokinase, and plasminogen activating complex. Based on application, the market is further segmented into myocardial infarction, pulmonary embolism, deep vein thrombosis, acute ischemic strokes, and others. Distribution channel segment of the market is also fragmented into retail pharmacies, hospital pharmacies, and online pharmacies. The market analysis also studies the regional segmentation to devise regional market segmentation, divided among Asia-Pacific region, North American region, European region, South American region, and Middle East & African region.

Company Profile

F. Hoffmann-La Roche AG, Taj Pharmaceuticals Limited, Eumedica Pharmaceuticals SA, SEDICO Pharmaceutical Company, Mochida Pharmaceutical Co., Ltd, Medac GmbH, Microbix Biosystems Inc, Crinos S.p.A., are enlisted in a partial list of major market players of the global clot buster drugs market. The existing market players are highly invested in research and product development along with viable service provisions for the consumers. New market entrants may follow similar strategies along with merger and acquisition methods for future brand establishment.

Report Scope:

In this report, global clot buster drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Clot Buster Drugs Market, By Type:

Fibrin Specific Drugs

  • Tissue Plasminogen Activator
  • Reteplase
  • Tenecteplase
  • Others

Non-Fibrin Specific Drugs

  • Urokinase
  • Streptokinase
  • Plasminogen Activating Complex
  • Clot Buster Drugs Market, By Application:

Myocardial Infarction

Pulmonary Embolism

Deep Vein Thrombosis

Acute Ischemic Strokes

Others

  • Clot Buster Drugs Market, By Distribution Channel:

Retail Pharmacies

Hospital Pharmacies

Online Pharmacies

  • Clot Buster Drugs Market, By Region:

North America

  • United States
  • Mexico
  • Canada

Europe

  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Australia

Middle East & Africa

  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt

South America

  • Brazil
  • Argentina
  • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global clot buster drugs market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Clot Buster Drugs Market

4. Executive Summary

5. Voice of Customer

  • 5.1. Preference, By Drug Type
  • 5.2. Factors Contributing to Higher Demand of Clot Buster Drugs
  • 5.3. Barriers to Adoption of Clot Buster Drugs
  • 5.4. Brand Awareness

6. Clinical Trials

  • 6.1. Ongoing Clinical Trials
  • 6.2. Completed Clinical Trials
  • 6.3. Terminated Clinical Trials
  • 6.4. Clinical Trial Analysis

7. Patent Analysis

  • 7.1. Patent Granted (2016-2020)
  • 7.2. Patent Applications Filed

8. Global Clot Buster Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type (Fibrin Specific Drugs v/s Non-Fibrin Specific Drugs)
      • 8.2.1.1. By Fibrin Specific Drugs (Tissue Plasminogen Activator, Reteplase, Tenecteplase, Others)
      • 8.2.1.2. By Non-Fibrin Specific Drugs (Urokinase, Streptokinase, Plasminogen Activating Complex)
    • 8.2.2. By Application (Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis, Acute Ischemic Strokes, Others)
    • 8.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 8.2.4. By Company (2021)
    • 8.2.5. By Region
  • 8.3. Product Market Map

9. North America Clot Buster Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type (Fibrin Specific Drugs v/s Non-Fibrin Specific Drugs)
      • 9.2.1.1. By Fibrin Specific Drugs (Tissue Plasminogen Activator, Reteplase, Tenecteplase, Others)
      • 9.2.1.2. By Non-Fibrin Specific Drugs (Urokinase, Streptokinase, Plasminogen Activating Complex)
    • 9.2.2. By Application (Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis, Acute Ischemic Strokes, Others)
    • 9.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 9.2.4. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Clot Buster Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Mexico Clot Buster Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Canada Clot Buster Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Distribution Channel

10. Europe Clot Buster Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type (Fibrin Specific Drugs v/s Non-Fibrin Specific Drugs)
      • 10.2.1.1. By Fibrin Specific Drugs (Tissue Plasminogen Activator, Reteplase, Tenecteplase, Others)
      • 10.2.1.2. By Non-Fibrin Specific Drugs (Urokinase, Streptokinase, Plasminogen Activating Complex)
    • 10.2.2. By Application (Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis, Acute Ischemic Strokes, Others)
    • 10.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 10.2.4. By Country
  • 10.3. Europe: Country Analysis
    • 10.3.1. France Clot Buster Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Germany Clot Buster Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. United Kingdom Clot Buster Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Distribution Channel
    • 10.3.4. Italy Clot Buster Drugs Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Type
        • 10.3.4.2.2. By Application
        • 10.3.4.2.3. By Distribution Channel
    • 10.3.5. Spain Clot Buster Drugs Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Type
        • 10.3.5.2.2. By Application
        • 10.3.5.2.3. By Distribution Channel

11. Asia-Pacific Clot Buster Drugs Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type (Fibrin Specific Drugs v/s Non-Fibrin Specific Drugs)
      • 11.2.1.1. By Fibrin Specific Drugs (Tissue Plasminogen Activator, Reteplase, Tenecteplase, Others)
      • 11.2.1.2. By Non-Fibrin Specific Drugs (Urokinase, Streptokinase, Plasminogen Activating Complex)
    • 11.2.2. By Application (Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis, Acute Ischemic Strokes, Others)
    • 11.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 11.2.4. By Country
  • 11.3. Asia-Pacific: Country Analysis
    • 11.3.1. China Clot Buster Drugs Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Type
        • 11.3.1.2.2. By Application
        • 11.3.1.2.3. By Distribution Channel
    • 11.3.2. India Clot Buster Drugs Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Type
        • 11.3.2.2.2. By Application
        • 11.3.2.2.3. By Distribution Channel
    • 11.3.3. South Korea Clot Buster Drugs Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Type
        • 11.3.3.2.2. By Application
        • 11.3.3.2.3. By Distribution Channel
    • 11.3.4. Japan Clot Buster Drugs Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Type
        • 11.3.4.2.2. By Application
        • 11.3.4.2.3. By Distribution Channel
    • 11.3.5. Australia Clot Buster Drugs Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Type
        • 11.3.5.2.2. By Application
        • 11.3.5.2.3. By Distribution Channel

12. South America Clot Buster Drugs Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Type (Fibrin Specific Drugs v/s Non-Fibrin Specific Drugs)
      • 12.2.1.1. By Fibrin Specific Drugs (Tissue Plasminogen Activator, Reteplase, Tenecteplase, Others)
      • 12.2.1.2. By Non-Fibrin Specific Drugs (Urokinase, Streptokinase, Plasminogen Activating Complex)
    • 12.2.2. By Application (Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis, Acute Ischemic Strokes, Others)
    • 12.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 12.2.4. By Country
  • 12.3. South America: Country Analysis
    • 12.3.1. Brazil Clot Buster Drugs Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Type
        • 12.3.1.2.2. By Application
        • 12.3.1.2.3. By Distribution Channel
    • 12.3.2. Argentina Clot Buster Drugs Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Type
        • 12.3.2.2.2. By Application
        • 12.3.2.2.3. By Distribution Channel
    • 12.3.3. Colombia Clot Buster Drugs Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Type
        • 12.3.3.2.2. By Application
        • 12.3.3.2.3. By Distribution Channel

13. Middle East and Africa Clot Buster Drugs Market Outlook

  • 13.1. Market Size & Forecast
    • 13.1.1. By Value
  • 13.2. Market Share & Forecast
    • 13.2.1. By Type (Fibrin Specific Drugs v/s Non-Fibrin Specific Drugs)
      • 13.2.1.1. By Fibrin Specific Drugs (Tissue Plasminogen Activator, Reteplase, Tenecteplase, Others)
      • 13.2.1.2. By Non-Fibrin Specific Drugs (Urokinase, Streptokinase, Plasminogen Activating Complex)
    • 13.2.2. By Application (Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis, Acute Ischemic Strokes, Others)
    • 13.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 13.2.4. By Country
  • 13.3. MEA: Country Analysis
    • 13.3.1. South Africa Clot Buster Drugs Market Outlook
      • 13.3.1.1. Market Size & Forecast
        • 13.3.1.1.1. By Value
      • 13.3.1.2. Market Share & Forecast
        • 13.3.1.2.1. By Type
        • 13.3.1.2.2. By Application
        • 13.3.1.2.3. By Distribution Channel
    • 13.3.2. Saudi Arabia Clot Buster Drugs Market Outlook
      • 13.3.2.1. Market Size & Forecast
        • 13.3.2.1.1. By Value
      • 13.3.2.2. Market Share & Forecast
        • 13.3.2.2.1. By Type
        • 13.3.2.2.2. By Application
        • 13.3.2.2.3. By Distribution Channel
    • 13.3.3. UAE Clot Buster Drugs Market Outlook
      • 13.3.3.1. Market Size & Forecast
        • 13.3.3.1.1. By Value
      • 13.3.3.2. Market Share & Forecast
        • 13.3.3.2.1. By Type
        • 13.3.3.2.2. By Application
        • 13.3.3.2.3. By Distribution Channel
    • 13.3.4. Egypt Clot Buster Drugs Market Outlook
      • 13.3.4.1. Market Size & Forecast
        • 13.3.4.1.1. By Value
      • 13.3.4.2. Market Share & Forecast
        • 13.3.4.2.1. By Type
        • 13.3.4.2.2. By Application
        • 13.3.4.2.3. By Distribution Channel

14. Market Dynamics

  • 14.1. Drivers
  • 14.2. Challenges

15. Market Trends & Developments

16. Competitive Landscape

  • 16.1. F. Hoffmann-La Roche AG
  • 16.2. Taj Pharmaceuticals Limited
  • 16.3. Eumedica Pharmaceuticals SA
  • 16.4. SEDICO Pharmaceutical Company
  • 16.5. Mochida Pharmaceutical Co., Ltd
  • 16.6. Medac GmbH
  • 16.7. Microbix Biosystems Inc
  • 16.8. Crinos S.p.A.

17. Strategic Recommendations

18. About Us & Disclaimer